


**Investigation on the cardio-protective effect of Xin Su Ning on ischemia-reperfusion induced injury in isolated heart.**

T. Wang<sup>1</sup>, W. Xie<sup>2</sup>, C. Ellory<sup>1</sup>, R. Wilkins<sup>1</sup>, Y. Zhu<sup>2</sup>, Y. Ma<sup>1</sup>. <sup>1</sup>Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom, <sup>2</sup>Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

**Introduction:** We previously reported that Xin Su Ning (XSN) prolongs action potential duration (APD) of isolated cardiac myocytes<sup>1,2</sup>. In this study we aimed to identify the cardio-protective effect of XSN in Ischemia-reperfusion (I/R) induced injury in isolated heart.

**Methods:** CHL cell line stably transfected human NaV1.5 channel were used for electrophysiological assay using Axopatch 200B patch clamp system with external and internal solutions prepared as previously described<sup>3</sup>. For isolated hearts study, male Sprague-Dawley rats (280 ~ 320g) were divided into control, I/R, XSN 0.05 g/L and 0.1 g/L groups. The hearts were isolated and perfused in retrograde mode at constant pressure of 60 mmHg at 37°C as previously reported<sup>3</sup>. The extracts of XSN in the form of frozen dried powder were administrated by dissolving in the perfusing solution. The measurements used to evaluate XSN's effects were: Left ventricular developed pressure (LVDP), the rate of pressure development and rate of relaxation (max/min dP/dt), and heart rate (HR). Rate pressure product (RPP) was calculated by multiplying LVDP by HR. The differences between control and other groups were tested using Student's *t*-test.

**Results:** XSN blocks human NaV1.5 channel in a dose dependent manner with an  $IC_{50} = 0.184 \pm 0.017$  g/L. XSN at 0.1 g/L produced the significant recovery of LVDP during 60 min reperfusion as shown in Figure 1. Max dP/dt, min dP/dt and HR after 60 min perfusion with vehicle and difference concentrations of XSN were shown in Table 1.



**Fig. 1** (A) Dose response curve of XSN on human NaV1.5 channel (n=5); (B) Experimental protocol of contractile function of I/R perfused rat heart; (C) percent rate of LVDP of rat hearts with/without XSN treatment after reperfusion 0, 5, 10, 20, 30, 40, 60 min (n=5). The data were presented as mean±SEM. \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  vs. I/R group.

**Table 1** Myocardial contractile function measured ex vivo in a rat I/R heart (mean±SEM, n=5).

%pre-ischemia	LVDP	max dP/dt	min dP/dt	HR	RPP
I/R	48.11±2.18	56.82±4.91	48.06±3.67	97.61±5.80	46.82±3.06
XSN 0.05 g/L	61.28±6.08	57.50±7.82	58.07±6.05*	79.15±4.34	48.85±6.43
XSN 0.1 g/L	87.36±4.34***	93.39±4.53**	90.27±4.25***	75.56±3.94*	70.57±5.38**

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$  vs. I/R group.

**Conclusions:** XSN blocked NaV1.5 channel dose dependently, and together with the APD prolongation which could be the cellular electrophysiological mechanisms of the anti-tachyarrhythmic effect of XSN. XSN improved cardiac systolic function on ischemia-reperfusion injured rat heart by increasing LVDP, RPP, max dP/dt and min dP/dt, the protective effect may contribute to the anti-arrhythmic effect of XSN on ischemic heart.

**References:**

1. Ma Y-L et al. (2015). Proceedings of the British Pharmacological Society at <http://www.pA2online.org/abstracts/Vol16Issue1abst093P.pdf>.
2. Zhai J et al. (2017). The Lancet 390:S61.
3. Mavropoulos SA et al. (2017). Mol Med 23: 120-133.